Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Content
- Protease and inhibitor activities
- Known proteases in the human genome
- Human thiol-dependent cathepsins
- The term "cathepsin"
- Cathepsin K structure, expression and activity
- Cathepsin K structure
- Cathepsin K domain structure
- Cathepsin K tissue distribution
- Cathepsin K substrate specificity
- Inhibition of cathepsin K
- Cleavage of type I collagen by cathepsin K
- What makes cathepsin K a unique collagenase?
- Cathepsin K hydrolyses triple helical collagen
- Activity of cathepsin K
- Effect of chondroitin sulfate (CS)
- Cathepsin K/CS complex identification
- Cathepsin K/chondroitin complex formation
- Collagenolytic activity and complex formation
- Evidence that cathepsin K complexes exist in vivo
- Pycnodysostosis
- Pycno mutant Y212C has no collagenase activity
- Pycno mutant Y212C does not form complexes
- Collagens degradation by MMPs and cathepsins
- Cathepsin K in osteoporosis
- The human skeleton
- Osteoclast activity
- Cathepsin K and its expression in osteoclasts
- Osteoporosis
- Bone resorption assay (pit assay)
- Effect of inhibitors of cathepsins K and L
- Ratio of urine NTx/creatinine
- Cathepsin K and osteoporosis (summary)
- Cathepsin K in arthritis
- Arthritis
- Rheumatoid arthritis (RA)
- Cell types involved in cartilage and bone erosion
- Major bone and cartilage matrix proteins
- Cathepsin K expression in the inflamed synovium
- Expression of cathepsin K in the RA synovium
- Cartilage erosion by CATK+ cells
- Synovial cathepsin K expression and HFCQ
- Scanning EM of MMP/cathepsin-digested cartilage
- Inflammatory reaction involvement of cathepsin K
- MHC class II antigen presentation
- Expression of cathepsins K and S
- Cathepsin K deficiency and CIA
- Collagen-induced arthritis and cathepsins
- Type II CIA (experimental model)
- Ankle thickness of CIA
- Diminished susceptibility to CIA
- Bone erosion and cartilage damage
- Cartilage degradation
- Bone erosion
- Potential cathepsin inhibitor therapy in RA
- Conclusions
Topics Covered
- Cysteine proteases
- Cathepsin family
- Expression of cathepsins and their activity
- Collagen degradation
- Pycnodysostosis
- Cathepsin K in osteoporosis
- Cathepsin K in arthritis
- Mouse model of arthritis
Talk Citation
Bromme, D. (2007, October 1). Cathepsin K in bone and joint diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 26, 2024, from https://doi.org/10.69645/XAAT4684.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Dieter Bromme has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.